双效血管紧张素受体-脑啡肽酶抑制剂沙库巴曲/缬沙坦的研究进展

Sacubitril/valsartan, a dual angiotensin receptor and neprilysin inhibitior

沙库巴曲/缬沙坦(Entresto)是由诺华公司开发的双效血管紧张素受体-脑啡肽酶抑制剂,临床上可用于高血压和心力衰竭的治疗。该药由作用于脑啡肽酶的沙库巴曲和作用于肾素-血管紧张素-醛固酮系统的缬沙坦组成,可有效改善心力衰竭症状、降低血压并可积极改善肾功能,是一种理想的心力衰竭治疗药物。本文综述沙库巴曲/缬沙坦的作用机制、疗效、安全性及耐受性,以期能为临床治疗提供新的方向。

Sacubitril/valsartan(Entresto) is the dual angiotensin receptor-neprilysin inhibitor developed by Novartis, which can be used in the treatment of hypertension and heart failure. Entresto is composed of sacubitril and valsartan, and acts on both enkephalinase and renin-angiotensin-aldosterone system. Studies found that the sacubitril/valsartan can effectively improve heart failure symptom and renal function, and lower blood pressure. This review summarizes the clinical use of sacubitril/valsartan including its mechanism, efficacy, safety and tolerability to provide a new direction for clinical treatment.